FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912209278> ?p ?o ?g. }

• W2912209278 endingPage "115" @default.
• W2912209278 startingPage "115" @default.
• W2912209278 abstract "During the last two decades and until recently, there has been an annual increase of about 2% in the global incidence of renal cell cancer (RCC) while in Europe, the overall mortality rates for RCC increases again in recent years.[1] Surgical therapy remains the mainstay of therapy to achieve a cure in the management of RCC. For solitary renal tumors up to a diameter of 7 cm (T1), nephron-sparing surgery is the standard procedure, whereas radical nephrectomy is the necessary treatment for more advanced stages.[2] Recent advances in molecular biology have led to the development of several novel agents for the treatment of metastatic RCC (mRCC). Vascular endothelial growth factor-pathway inhibitors (sunitinib, sorafenib, pazopanib, bevacizumab, axitinib) and mammalian target of rapamycin-inhibitors (everolimus and temsirolimus) has substantially improved the outcomes of patients with mRCC.[3] Moreover, the above molecules are increasingly being used preoperatively to achieve cytoreduction. There are many advantages of administering molecular treatment with targeting molecules before planned definitive surgery to patients with non-metastatic RCC. First of all therapy is delivered at the earliest time-point, when the burden of micrometastatic disease is expected to be low. In addition tolerability of therapy is expected to be better before surgery rather than after, whereas patients with micrometastatic disease might respond to neo-adjuvant therapy and reveal a favorable pathological status. Moreover, a possible reduce of tumor size could make it more amenable to surgery.[4] Overtreatment of non-responders and those in the non-target population (i.e. patients without micrometastatic disease) is a major drawback in using neo-adjuvant therapy while delayed surgery might compromise the outcome in patients not sensitive to targeted treatment. In addition, hemorrhagic and wound healing issues have emerged and a significant increase in the incidence and severity of intraoperative adhesions have been shown in several studies.[5] The response of the primary tumor to the targeted molecular treatment seems to be unpredictable and relatively less compared with the metastatic tumor. A period of presurgical targeted therapy may identify those patients with rapid disease progression prior to a planned nephrectomy or metastasectomy from which they may not benefit. In non-randomized prospective studies of presurgical therapy, up to 26% of patients progressed at metastatic sites prior to plann surgery. Those with intermediate risk and absence of progression had a more than 70% probability to survive 2 years or longer after nephrectomy.[6] Sunitinib is the most potent agent which showed the maximum response in neo adjuvant treatment. Studies have shown that it caused the maximum reduction in the tumor size and the regression of tumor thrombus.[7] Moreover there is a report of complete radiological and histological regression of tumor with Sunitinib but the response is very unpredictable.[8] Currently, there is no indication for neo-adjuvant or adjuvant therapy for RCC, outside controlled clinical trials.[2] The small number of patients in this study limit the ability to widely extrapolate the results. Major methodological biases preclude any firm conclusion regarding the routine use of adjuvant therapy. However, this study adds to the body of literature suggesting that sunitinib based pre-operative therapy may have a role in renal cancer. The optimal neo-adjuvant strategy remains to be determined. Predictive biomarkers are urgently needed in order to determine, which patients are more likely to benefit from neo-adjuvant pharmaceutical therapy." @default.
• W2912209278 created "2019-02-21" @default.
• W2912209278 creator A5075410399 @default.
• W2912209278 date "2019-01-01" @default.
• W2912209278 modified "2023-10-02" @default.
• W2912209278 title "Neoadjuvant targeted therapy for advanced renal cell carcinoma: Where do we stand?" @default.
• W2912209278 cites W1903564775 @default.
• W2912209278 cites W1994485684 @default.
• W2912209278 cites W1996314285 @default.
• W2912209278 cites W2065859567 @default.
• W2912209278 cites W2076857293 @default.
• W2912209278 cites W2105871052 @default.
• W2912209278 cites W2140898380 @default.
• W2912209278 cites W2164317031 @default.
• W2912209278 cites W2911611736 @default.
• W2912209278 doi "https://doi.org/10.4103/0974-7796.250549" @default.
• W2912209278 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6362785" @default.
• W2912209278 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30787586" @default.
• W2912209278 hasPublicationYear "2019" @default.
• W2912209278 type Work @default.
• W2912209278 sameAs 2912209278 @default.
• W2912209278 citedByCount "4" @default.
• W2912209278 countsByYear W29122092782020 @default.
• W2912209278 countsByYear W29122092782021 @default.
• W2912209278 countsByYear W29122092782022 @default.
• W2912209278 countsByYear W29122092782023 @default.
• W2912209278 crossrefType "journal-article" @default.
• W2912209278 hasAuthorship W2912209278A5075410399 @default.
• W2912209278 hasBestOaLocation W29122092781 @default.
• W2912209278 hasConcept C121608353 @default.
• W2912209278 hasConcept C126322002 @default.
• W2912209278 hasConcept C141071460 @default.
• W2912209278 hasConcept C143998085 @default.
• W2912209278 hasConcept C183713625 @default.
• W2912209278 hasConcept C185592680 @default.
• W2912209278 hasConcept C190283241 @default.
• W2912209278 hasConcept C197934379 @default.
• W2912209278 hasConcept C2776539811 @default.
• W2912209278 hasConcept C2776694085 @default.
• W2912209278 hasConcept C2776820818 @default.
• W2912209278 hasConcept C2777472916 @default.
• W2912209278 hasConcept C2777802072 @default.
• W2912209278 hasConcept C2777982462 @default.
• W2912209278 hasConcept C2778019345 @default.
• W2912209278 hasConcept C2778375690 @default.
• W2912209278 hasConcept C2778439243 @default.
• W2912209278 hasConcept C2778695046 @default.
• W2912209278 hasConcept C2779490328 @default.
• W2912209278 hasConcept C2779699572 @default.
• W2912209278 hasConcept C2780091579 @default.
• W2912209278 hasConcept C2780227381 @default.
• W2912209278 hasConcept C2781068499 @default.
• W2912209278 hasConcept C2781230642 @default.
• W2912209278 hasConcept C2908647359 @default.
• W2912209278 hasConcept C55493867 @default.
• W2912209278 hasConcept C71924100 @default.
• W2912209278 hasConcept C86554907 @default.
• W2912209278 hasConcept C99454951 @default.
• W2912209278 hasConceptScore W2912209278C121608353 @default.
• W2912209278 hasConceptScore W2912209278C126322002 @default.
• W2912209278 hasConceptScore W2912209278C141071460 @default.
• W2912209278 hasConceptScore W2912209278C143998085 @default.
• W2912209278 hasConceptScore W2912209278C183713625 @default.
• W2912209278 hasConceptScore W2912209278C185592680 @default.
• W2912209278 hasConceptScore W2912209278C190283241 @default.
• W2912209278 hasConceptScore W2912209278C197934379 @default.
• W2912209278 hasConceptScore W2912209278C2776539811 @default.
• W2912209278 hasConceptScore W2912209278C2776694085 @default.
• W2912209278 hasConceptScore W2912209278C2776820818 @default.
• W2912209278 hasConceptScore W2912209278C2777472916 @default.
• W2912209278 hasConceptScore W2912209278C2777802072 @default.
• W2912209278 hasConceptScore W2912209278C2777982462 @default.
• W2912209278 hasConceptScore W2912209278C2778019345 @default.
• W2912209278 hasConceptScore W2912209278C2778375690 @default.
• W2912209278 hasConceptScore W2912209278C2778439243 @default.
• W2912209278 hasConceptScore W2912209278C2778695046 @default.
• W2912209278 hasConceptScore W2912209278C2779490328 @default.
• W2912209278 hasConceptScore W2912209278C2779699572 @default.
• W2912209278 hasConceptScore W2912209278C2780091579 @default.
• W2912209278 hasConceptScore W2912209278C2780227381 @default.
• W2912209278 hasConceptScore W2912209278C2781068499 @default.
• W2912209278 hasConceptScore W2912209278C2781230642 @default.
• W2912209278 hasConceptScore W2912209278C2908647359 @default.
• W2912209278 hasConceptScore W2912209278C55493867 @default.
• W2912209278 hasConceptScore W2912209278C71924100 @default.
• W2912209278 hasConceptScore W2912209278C86554907 @default.
• W2912209278 hasConceptScore W2912209278C99454951 @default.
• W2912209278 hasIssue "1" @default.
• W2912209278 hasLocation W29122092781 @default.
• W2912209278 hasLocation W29122092782 @default.
• W2912209278 hasLocation W29122092783 @default.
• W2912209278 hasLocation W29122092784 @default.
• W2912209278 hasLocation W29122092785 @default.
• W2912209278 hasOpenAccess W2912209278 @default.
• W2912209278 hasPrimaryLocation W29122092781 @default.
• W2912209278 hasRelatedWork W1984657347 @default.
• W2912209278 hasRelatedWork W2041921283 @default.
• W2912209278 hasRelatedWork W2076823089 @default.

• next